Hans F A Vasen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8465248/publications.pdf Version: 2024-02-01

		38742	20961
126	13,823	50	115
papers	citations	h-index	g-index
132	132	132	10616
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62, 812-823.	12.1	630
2	Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology, 2004, 127, 17-25.	1.3	536
3	The risk of extraâ€colonic, extraâ€endometrial cancer in the Lynch syndrome. International Journal of Cancer, 2008, 123, 444-449.	5.1	481
4	Mutations Associated with HNPCC Predisposition — Update of ICG-HNPCC/INSiGHT Mutation Database. Disease Markers, 2004, 20, 269-276.	1.3	416
5	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	12.1	411
6	Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	12.1	410
7	Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature Genetics, 1999, 23, 142-144.	21.4	378
8	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	2.4	365
9	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
10	Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium â€~Care for CMMRD' (C4CMMRD). Journal of Medical Genetics, 2014, 51, 355-365.	3.2	351
11	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Journal of Clinical Oncology, 2016, 34, 2010-2019.	1.6	280
12	Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New England Journal of Medicine, 2008, 359, 2567-2578.	27.0	273
13	Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome. Journal of Clinical Oncology, 2012, 30, 4409-4415.	1.6	262
14	Decrease in Mortality in Lynch Syndrome Families Because of Surveillance. Gastroenterology, 2006, 130, 665-671.	1.3	246
15	One to 2-Year Surveillance Intervals Reduce Risk of Colorectal Cancer in Families With Lynch Syndrome. Gastroenterology, 2010, 138, 2300-2306.	1.3	219
16	The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer, 2002, 94, 1708-1712.	4.1	217
17	MSH2 genomic deletions are a frequent cause of HNPCC. Nature Genetics, 1998, 20, 326-328.	21.4	216
18	Risk and Epidemiological Time Trends of Gastric Cancer in Lynch Syndrome Carriers in The Netherlands. Gastroenterology, 2010, 138, 487-492.	1.3	201

#	Article	IF	CITATIONS
19	Microsatellite Instability, Immunohistochemistry, and Additional PMS2 Staining in Suspected Hereditary Nonpolyposis Colorectal Cancer. Clinical Cancer Research, 2004, 10, 972-980.	7.0	200
20	The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology, 2004, 126, 42-48.	1.3	199
21	The tumour spectrum in hereditary non-polyposis colorectal cancer: A study of 24 kindreds in the netherlands. International Journal of Cancer, 1990, 46, 31-34.	5.1	182
22	Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. Journal of Pathology, 2000, 192, 328-335.	4.5	168
23	MUTYH-associated polyposis (MAP). Critical Reviews in Oncology/Hematology, 2011, 79, 1-16.	4.4	163
24	Conventional and Tissue Microarray Immunohistochemical Expression Analysis of Mismatch Repair in Hereditary Colorectal Tumors. American Journal of Pathology, 2003, 162, 469-477.	3.8	159
25	A nationâ€wide study comparing sporadic and familial adenomatous polyposisâ€related desmoidâ€type fibromatoses. International Journal of Cancer, 2011, 129, 256-261.	5.1	154
26	Magnetic Resonance Imaging Surveillance Detects Early-Stage Pancreatic Cancer in Carriers of a p16-Leiden Mutation. Gastroenterology, 2011, 140, 850-856.	1.3	148
27	Cancer Risks for <i>PMS2</i> -Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	1.6	147
28	Heterozygous Mutations in PMS2 Cause Hereditary Nonpolyposis Colorectal Carcinoma (Lynch) Tj ETQq0 0 0 rg	BT/Qverlo	ck 10 Tf 50 3 132
29	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	12.1	127
30	Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. , 1998, 83, 240-244.		125
31	Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2002, 102, 198-200.	5.1	119
32	Cancer risk and genotype–phenotype correlations in PTEN hamartoma tumor syndrome. Familial Cancer, 2014, 13, 57-63.	1.9	119
33	Family History, Surgery, and APC Mutation Are Risk Factors for Desmoid Tumors in Familial Adenomatous Polyposis: An International Cohort Study. Diseases of the Colon and Rectum, 2011, 54, 1229-1234.	1.3	115
34	Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2004, 109, 468-471.	5.1	105
35	Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. European Journal of Human Genetics, 2015, 23, 1080-1084.	2.8	101
36	Clinical management of hereditary colorectal cancer syndromes. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 88-97.	17.8	99

#	Article	IF	CITATIONS
37	Functional Outcome After Colectomy and Ileorectal Anastomosis Compared With Proctocolectomy and Ileal Pouch–Anal Anastomosis in Familial Adenomatous Polyposis. Annals of Surgery, 1999, 230, 648.	4.2	99
38	Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1242-1249.	10.7	95
39	Desmoid Tumors in a Dutch Cohort of Patients With Familial Adenomatous Polyposis. Clinical Gastroenterology and Hepatology, 2008, 6, 215-219.	4.4	83
40	Chromosome 8q23.3 and 11q23.1 Variants Modify Colorectal Cancer Risk in Lynch Syndrome. Gastroenterology, 2009, 136, 131-137.	1.3	80
41	Quality of Life After Surgery for Colon Cancer in Patients With Lynch Syndrome. Diseases of the Colon and Rectum, 2012, 55, 653-659.	1.3	80
42	Long Term Follow-up of HNPCC Gene Mutation Carriers: Compliance with Screening and Satisfaction with Counseling and Screening Procedures. Familial Cancer, 2005, 4, 295-300.	1.9	79
43	The Natural Course of Multiple Endocrine Neoplasia Type iib. Archives of Internal Medicine, 1992, 152, 1250.	3.8	78
44	Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Gastroenterology, 2015, 149, 1017-1029.e3.	1.3	76
45	Prospective Results of Surveillance Colonoscopy in Dominant Familial Colorectal Cancer With and Without Lynch Syndrome. Gastroenterology, 2006, 130, 1995-2000.	1.3	72
46	Small-bowel cancer in Lynch syndrome: is it time for surveillance?. Lancet Oncology, The, 2008, 9, 901-905.	10.7	65
47	Body Mass Index Increases Risk of Colorectal Adenomas in Men With Lynch Syndrome: The GEOLynch Cohort Study. Journal of Clinical Oncology, 2010, 28, 4346-4353.	1.6	62
48	Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. Journal of Medical Genetics, 2010, 47, 99-102.	3.2	61
49	Surveillance for hereditary cancer: Does the benefit outweigh the psychological burden?—A systematic review. Critical Reviews in Oncology/Hematology, 2012, 83, 329-340.	4.4	60
50	Variation in Precursor Lesions of Pancreatic Cancer among High-Risk Groups. Clinical Cancer Research, 2013, 19, 442-449.	7.0	58
51	The "unnatural―history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. International Journal of Cancer, 2021, 148, 800-811.	5.1	55
52	Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18.	1.5	49
53	Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Gut, 2015, 64, 1578-1583.	12.1	47
54	Smoking Increases the Risk for Colorectal Adenomas in Patients With Lynch Syndrome. Gastroenterology, 2012, 142, 241-247.	1.3	44

#	Article	IF	CITATIONS
55	Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genetics in Medicine, 2020, 22, 1524-1532.	2.4	44
56	Germ Line Mutations of Mismatch Repair Genes in Hereditary Nonpolyposis Colorectal Cancer Patients with Small Bowel Cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study: Table 1 Clinical Cancer Research, 2006, 12, 3389-3393.	7.0	42
57	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	1.5	42
58	Attitudes toward genetic testing in childhood and reproductive decision-making for familial adenomatous polyposis. European Journal of Human Genetics, 2010, 18, 186-193.	2.8	38
59	Loss-of-Function Mutations in the Cell-Cycle Control Gene <i>CDKN2A</i> Impact on Glucose Homeostasis in Humans. Diabetes, 2016, 65, 527-533.	0.6	38
60	Dietary patterns and colorectal adenomas in Lynch syndrome. Cancer, 2013, 119, 512-521.	4.1	37
61	Colorectal surveillance in Lynch syndrome families. Familial Cancer, 2013, 12, 261-265.	1.9	36
62	Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non- <i>BRCA1/2</i> breast cancer families. Journal of Medical Genetics, 2019, 56, 581-589.	3.2	35
63	Combined analysis of three lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. International Journal of Cancer, 2013, 132, 1556-1564.	5.1	33
64	Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant. European Journal of Human Genetics, 2015, 23, 711-714.	2.8	29
65	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	2.4	28
66	Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry. Familial Cancer, 2016, 15, 429-435.	1.9	25
67	Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer. Scientific Reports, 2015, 5, 16286.	3.3	24
68	Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. Journal of Clinical Pathology, 2017, 70, 174-178.	2.0	24
69	A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. International Journal of Cancer, 2014, 134, 939-947.	5.1	22
70	Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden). Clinical Cancer Research, 2003, 9, 3598-605.	7.0	22
71	The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family. Familial Cancer, 2007, 6, 43-51.	1.9	21
72	Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4188-4193.	1.6	21

#	Article	IF	CITATIONS
73	Duodenal Adenomas and Cancer in MUTYH-associated Polyposis: An International Cohort Study. Gastroenterology, 2021, 160, 952-954.e4.	1.3	20
74	Equivalent Helicobacter pylori infection rates in Lynch syndrome mutation carriers with and without a first-degree relative with gastric cancer. International Journal of Colorectal Disease, 2016, 31, 693-697.	2.2	18
75	Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations. BMC Medical Genetics, 2007, 8, 42.	2.1	17
76	Transanal minimally invasive surgery (TAMIS) versus endoscopic submucosal dissection (ESD) for resection of non-pedunculated rectal lesions (TRIASSIC study): study protocol of a European multicenter randomised controlled trial. BMC Gastroenterology, 2020, 20, 225.	2.0	17
77	Incidence of small bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Endoscopy International Open, 2017, 05, E622-E626.	1.8	16
78	Lynch syndrome—how should colorectal cancer be managed?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 184-186.	17.8	15
79	The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers. Genetics in Medicine, 2016, 18, 405-409.	2.4	15
80	Psychological distress and quality of life following positive fecal occult blood testing in colorectal cancer screening. Psycho-Oncology, 2020, 29, 1084-1091.	2.3	15
81	Skin self-examination of persons from families with familial atypical multiple mole melanoma (FAMMM). Patient Education and Counseling, 2009, 75, 251-255.	2.2	14
82	Clinical Perspective on Proteomic and Clycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. International Journal of Molecular Sciences, 2021, 22, 2655.	4.1	14
83	Dietary B vitamin and methionine intake and MTHFR C677T genotype on risk of colorectal tumors in Lynch syndrome: the GEOLynch cohort study. Cancer Causes and Control, 2014, 25, 1119-1129.	1.8	13
84	CM-Score: a validated scoring system to predict <i>CDKN2A</i> germline mutations in melanoma families from Northern Europe. Journal of Medical Genetics, 2018, 55, 661-668.	3.2	13
85	Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic <i>CDKN2A</i> variants. Journal of Medical Genetics, 2021, 58, 264-269.	3.2	13
86	Declining detection rates for APC and biallelic MUTYH variants in polyposis patients, implications for DNA testing policy. European Journal of Human Genetics, 2020, 28, 222-230.	2.8	12
87	Bias in detection of instability of the (C)8 mononucleotide repeat of MSH6 in tumours from HNPCC patients. Oncogene, 2001, 20, 6241-6244.	5.9	11
88	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	2.8	11
89	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
90	Clinical utility gene card for: Familial adenomatous polyposis (FAP) and attenuated FAP (AFAP). European Journal of Human Genetics, 2011, 19, 832-832.	2.8	10

#	Article	IF	CITATIONS
91	Quality of colonoscopy in Lynch syndrome. Endoscopy International Open, 2014, 02, E252-E255.	1.8	10
92	Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case–control study. BMC Research Notes, 2015, 8, 264.	1.4	10
93	The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer. Familial Cancer, 2018, 17, 1-3.	1.9	10
94	Clinical Utility Gene Card for: Familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) - update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	2.8	9
95	Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Translational Oncology, 2016, 9, 242-247.	3.7	9
96	Diagnostic value of targeted next-generation sequencing in patients with suspected pancreatic or periampullary cancer. Journal of Clinical Pathology, 2018, 71, 246-252.	2.0	9
97	Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers. European Journal of Human Genetics, 2018, 26, 1227-1229.	2.8	9
98	Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques. Journal of Cancer Research and Clinical Oncology, 2015, 141, 531-541.	2.5	8
99	A new hereditary colorectal cancer network in the Middle East and eastern mediterranean countries to improve care for high-risk families. Familial Cancer, 2018, 17, 209-212.	1.9	8
100	Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps. Molecular Genetics & Genomic Medicine, 2019, 7, e00603.	1.2	8
101	Detection of pancreatic cancer using serum protein profiling. Hpb, 2013, 15, 602-610.	0.3	7
102	Dietary Supplement Use and Colorectal Adenoma Risk in Individuals with Lynch Syndrome: The GEOLynch Cohort Study. PLoS ONE, 2013, 8, e66819.	2.5	7
103	Colonoscopy in Lynch syndrome: the need for a new quality score. Familial Cancer, 2017, 16, 239-241.	1.9	7
104	Optimizing the timing of colorectal surgery in patients with familial adenomatous polyposis in clinical practice. Scandinavian Journal of Gastroenterology, 2019, 54, 733-739.	1.5	7
105	Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program. Hpb, 2019, 21, 1371-1375.	0.3	7
106	Value-based healthcare in Lynch syndrome. Familial Cancer, 2013, 12, 347-354.	1.9	6
107	A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants. Scientific Reports, 2021, 11, 11401.	3.3	6
108	8q23.3 and 11q23.1 as modifying loci influencing the risk for CRC in Lynch syndrome. European Journal of Human Genetics, 2012, 20, 487-488.	2.8	5

#	Article	IF	CITATIONS
109	Identification of familial colorectal cancer and hereditary colorectal cancer syndromes through the Dutch population-screening program: results ofa pilot study. Scandinavian Journal of Gastroenterology, 2016, 51, 1227-1232.	1.5	5
110	High Growth Rate of Pancreatic Ductal Adenocarcinoma in <i>CDKN2A-p16-Leiden</i> Mutation Carriers. Cancer Prevention Research, 2018, 11, 551-556.	1.5	5
111	A hundred years of Lynch syndrome research (1913–2013). Familial Cancer, 2013, 12, 141-142.	1.9	4
112	Progress Report: New insights into the prevention of CRC by colonoscopic surveillance in Lynch syndrome. Familial Cancer, 2022, 21, 49-56.	1.9	4
113	An Overview of the Lynch Syndrome (Hereditary Non-polyposis Colorectal Cancer). , 2010, , 271-299.		4
114	Constitutional or biallelic? Settling on a name for a recessively inherited cancer susceptibility syndrome. Journal of Medical Genetics, 2016, 53, 226-226.	3.2	3
115	Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. Familial Cancer, 2017, 16, 111-115.	1.9	3
116	Identification and management of Lynch syndrome in the Middle East and North African countries: outcome of a survey in 12 countries. Familial Cancer, 2020, 20, 215-221.	1.9	3
117	Is a colorectal neoplasm diagnosis a trigger to change dietary and other lifestyle habits for persons with Lynch syndrome? A prospective cohort study. Familial Cancer, 2021, 20, 125-135.	1.9	3
118	Endoscopic full thickness resection for early colon cancer in Lynch syndrome. Familial Cancer, 2019, 18, 349-352.	1.9	2
119	Diet quality and colorectal tumor risk in persons with Lynch syndrome. Cancer Epidemiology, 2020, 69, 101809.	1.9	2
120	Kluwer Academic Publishers. Annals of Oncology, 2001, 12, 735-735.	1.2	1
121	Clinical evidence for an association between familial adenomatous polyposis and type II diabetes. International Journal of Cancer, 2012, 131, 1488-1489.	5.1	1
122	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 125-126.	2.4	0
123	Reply to Win and Jenkins. International Journal of Cancer, 2013, 133, 1764-1764.	5.1	0
124	Reply to V. Bonadona et al. Journal of Clinical Oncology, 2013, 31, 2230-2230.	1.6	0
125	Familial Pancreatic Cancer: To Screen or not to Screen?. EBioMedicine, 2015, 2, 1858-1859.	6.1	0
126	Screening of Individuals at High Risk for Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2019, 17, 1916-1917.	4.4	0